Immunotherapy of Cervical Cancer

Guest Editor:

Dr. Takashi Iwata
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

Deadline for manuscript submissions:
closed (15 May 2022)

Message from the Guest Editor

A comprehensive understanding of tumor immunology has a certain promoting effect on the treatment of cervical cancer. Immune therapy including, but not limited to, the immune checkpoint blockade (ICB), adoptive cell transfer, therapeutic vaccines and cytokine treatment, has become a promising breakthrough in cancer treatment. This Special Issue will highlight the current state of tumor immunity in cervical cancer in all its diversity, covering both basic and (pre-)clinical aspects, advancing our knowledge to improve cervical cancer treatment.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us